The estimated Net Worth of Scott A Canute is at least $1.88 Milion dollars as of 9 November 2016. Mr. Canute owns over 57,971 units of Flexion Therapeutics Inc stock worth over $1,736,303 and over the last 19 years he sold FLXN stock worth over $0. In addition, he makes $141,184 as Independent Director at Flexion Therapeutics Inc.
Sign up
Mr. Canute FLXN stock SEC Form 4 insiders trading
Scott has made over 3 trades of the Flexion Therapeutics Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 57,971 units of FLXN stock worth $532,753 on 9 November 2016.
The largest trade he's ever made was exercising 57,971 units of Flexion Therapeutics Inc stock on 9 November 2016 worth over $532,753. On average, Scott trades about 1,707 units every 100 days since 2005. As of 9 November 2016 he still owns at least 188,934 units of Flexion Therapeutics Inc stock.
You can see the complete history of Mr. Canute stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Scott Canute biography
Scott A. Canute serves as Independent Director of the Company. Mr. Canute has served as one of our directors since 2015. Mr. Canute served as President of Global Manufacturing and Corporate Operations at Genzyme Corporation from 2010 to 2011. Prior to joining Genzyme, Mr. Canute spent 25 years at Eli Lilly and Company and served as President, Global Manufacturing Operations from 2004 to 2007. Mr. Canute currently serves as Executive Director of Immunomedics, Inc., a biopharmaceutical company focused on antibody drug conjugates, and he serves on the board of directors of Proteon Therapeutics, a biopharmaceutical company focused on renal and vascular disease; and Akebia Therapeutics, Inc., a publicly traded biopharmaceutical company focused on renal disease. Mr. Canute previously served as a member of the board of directors of AlloCure, Inc., Inspiration Biopharmaceuticals, Inc., Oncobiologics, Inc., the National Association of Manufacturers and the Indiana Manufacturers Association. Mr. Canute earned a B.S. in chemical engineering from the University of Michigan and an M.B.A. from Harvard Business School. Our Board believes that Mr. Canute’s manufacturing and operational experience in the biopharmaceutical industry and his experience of serving on the board of directors for several biopharmaceuticals companies qualifies Mr. Canute to serve on our Board of Directors.
What is the salary of Scott Canute?
As the Independent Director of Flexion Therapeutics Inc, the total compensation of Scott Canute at Flexion Therapeutics Inc is $141,184. There are 11 executives at Flexion Therapeutics Inc getting paid more, with Michael Clayman having the highest compensation of $3,777,360.
How old is Scott Canute?
Scott Canute is 59, he's been the Independent Director of Flexion Therapeutics Inc since 2015. There are 6 older and 9 younger executives at Flexion Therapeutics Inc. The oldest executive at Flexion Therapeutics Inc is Samuel Colella, 80, who is the Independent Director.
What's Scott Canute's mailing address?
Scott's mailing address filed with the SEC is C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE, MA, 02139.
Insiders trading at Flexion Therapeutics Inc
Over the last 11 years, insiders at Flexion Therapeutics Inc have traded over $7,066,621 worth of Flexion Therapeutics Inc stock and bought 7,091,809 units worth $98,920,816 . The most active insiders traders include Holdings A/S Novo, Bradley J Ph D Bolzon a Samuel D Colella. On average, Flexion Therapeutics Inc executives and independent directors trade stock every 24 days with the average trade being worth of $609,564. The most recent stock trade was executed by Christina Willwerth on 19 July 2021, trading 3,945 units of FLXN stock currently worth $25,445.
What does Flexion Therapeutics Inc do?
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.
What does Flexion Therapeutics Inc's logo look like?
Complete history of Mr. Canute stock trades at Akebia Therapeutics, Flexion Therapeutics Inc, Immunomedics, Lilly(Eli) & Co a Oncorus
Flexion Therapeutics Inc executives and stock owners
Flexion Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Michael Clayman,
President, Chief Executive Officer, Director -
David Arkowitz,
Chief Financial Officer -
Scott Kelley,
Chief Medical Officer -
Mark Levine,
General Counsel and Corporate Secretary -
Dr. Neil Bodick,
Consultant -
Patrick Mahaffy,
Independent Chairman of the Board -
Sandesh Mahatme,
Independent Director -
Samuel Colella,
Independent Director -
Alan Milinazzo,
Independent Director -
Mark Stejbach,
Independent Director -
C. Ann Merrifield,
Independent Director -
Scott Canute,
Independent Director -
Heath Lukatch,
Independent Director -
Scott Young,
IR Contact Officer -
Elizabeth Kwo,
Director -
Christina Willwerth,
Chief Strategy Officer -
Kerry Wentworth,
Chief Regulatory Officer -
Melissa Layman,
Chief Commercial Officer -
John Magee,
VP of Sales -
Carolyn Beaty Scimemi,
VP, Legal Affairs & Chief Compliance Officer -
David A. Arkowitz M.B.A.,
Chief Financial Officer -
Ventures Iii, Llc Versant V...,
-
Yamo Deniz,
Chief Medical Officer -
Frederick W Driscoll,
Chief Financial Officer -
Barbara N Bolzon Bradley J ...,
-
William T. Andrews,
Chief Medical Officer -
Utpal Koppikar,
Director -
Neil Bodick,
Chief Scientific Officer -
Ventures Ii Lp5 Am Co Inves...,
-
Holdings A/S Novo,
10% owner -
Partners Sas Sofinnova,
10% owner -
Venture Capital Iii, L.P.Bo...,
-
Venture Capital Iii, L.P.Ve...,
-
Rafael Tordjman,
Director -
Andrew J. Schwab,
Director -
Bradley J Ph D Bolzon,
Director -
Venture Capital Iii, L.P.Ve...,
-
Inc Pfizer,
10% owner -
Management, Llc Newtyn,
10% owner -
Adam Muzikant,
Chief Business Officer